^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Thyroid Gland Anaplastic Carcinoma |
| Drug: | Tafinlar (dabrafenib) (BRAF inhibitor) + SCH772984 (ERK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo
Published date:
02/17/2021
Excerpt:
...we examined the effect of combined BRAF inhibition (dabrafenib) and ERK1/2 inhibition (SCH772984) on the growth and survival of a panel of BRAF-mutant thyroid cancer cell lines using in vitro and in vivo approaches...Combined inhibition also results in synergistic growth inhibition, decreased clonogenic survival, and enhanced induction of apoptosis in a subset of BRAF-mutant thyroid cancer cells. Finally, combined inhibition of BRAF and ERK1/2 results in enhanced inhibition of tumor growth in an anaplastic thyroid cancer in vivo model.
Secondary therapy:
everolimus + letrozole
DOI:
10.1002/mc.23284
